{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-21-049470","form_type":"8-K","ticker":"ATNM","cik":"0001388320","company_name":"Actinium Pharmaceuticals, Inc.","filed_at":"2021-09-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.914017+00:00","generated_at":"2026-06-29T01:45:06.928944+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Actinium appoints Swaminathan as Chief Business Officer, Desai as CMO; Berger resigns","bullets":["Mark Berger resigns as CMO effective Sept 24, 2021; no disagreement with company.","Arun Swaminathan, Ph.D., appointed Chief Business and Commercial Officer; previously at Alteogen, BMS.","Avinash Desai, M.D., promoted to CMO from EVP Clinical Development; will lead BLA filing for Iomab-B.","Paul Diamond, Ph.D., appointed VP Patent and Legal Counsel; 20+ years IP experience.","Phase 3 SIERRA trial enrollment complete; commercial planning for Iomab-B begins."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-21-049470","json":"https://secwatch.observer/filing/0001213900-21-049470.json","markdown":"https://secwatch.observer/filing/0001213900-21-049470.md","text":"https://secwatch.observer/filing/0001213900-21-049470.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1388320/000121390021049470/0001213900-21-049470-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1388320/000121390021049470/ea147815-8k_actinium.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T01:45:06.928944+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"faea3e6785","claim":"Mark S. Berger resigned as Chief Medical Officer at Actinium Pharmaceuticals, Inc..","evidence_excerpt":"Dr. Mark S. Berger, the Chief Medical Officer of Actinium Pharmaceuticals, Inc. (the “Company”), notified the Company that he will be resigning effective as of September 24, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390021049470/0001213900-21-049470-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}